Brokerages Expect Horizon Pharma PLC (HZNP) to Announce $0.22 Earnings Per Share

Equities analysts predict that Horizon Pharma PLC (NASDAQ:HZNP) will report $0.22 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Horizon Pharma’s earnings, with the highest EPS estimate coming in at $0.25 and the lowest estimate coming in at $0.19. Horizon Pharma posted earnings of $0.66 per share during the same quarter last year, which would indicate a negative year over year growth rate of 66.7%. The business is scheduled to announce its next earnings report on Monday, February 26th.

According to Zacks, analysts expect that Horizon Pharma will report full-year earnings of $1.10 per share for the current financial year, with EPS estimates ranging from $1.05 to $1.14. For the next year, analysts expect that the firm will report earnings of $1.29 per share, with EPS estimates ranging from $1.04 to $1.40. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that follow Horizon Pharma.

Horizon Pharma (NASDAQ:HZNP) last issued its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.22 by $0.04. Horizon Pharma had a positive return on equity of 20.22% and a negative net margin of 45.28%. The company had revenue of $271.60 million for the quarter, compared to analysts’ expectations of $259.74 million. During the same period in the prior year, the firm earned $0.70 earnings per share. The firm’s revenue for the quarter was up 30.1% on a year-over-year basis.

A number of research firms recently commented on HZNP. ValuEngine cut Horizon Pharma from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Jefferies Group increased their target price on Horizon Pharma from $16.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, November 7th. Stifel Nicolaus reiterated a “buy” rating and set a $20.00 target price on shares of Horizon Pharma in a research report on Sunday, October 22nd. Piper Jaffray Companies set a $18.00 price target on Horizon Pharma and gave the company a “buy” rating in a research note on Sunday, September 10th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $17.00 price target on shares of Horizon Pharma in a research note on Monday, September 11th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $18.75.

Several hedge funds have recently bought and sold shares of the company. Sheaff Brock Investment Advisors LLC grew its position in shares of Horizon Pharma by 5.0% in the second quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 500 shares in the last quarter. Prudential Financial Inc. lifted its stake in Horizon Pharma by 5.0% during the second quarter. Prudential Financial Inc. now owns 17,510 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 830 shares in the last quarter. Amalgamated Bank lifted its stake in Horizon Pharma by 4.8% during the second quarter. Amalgamated Bank now owns 20,711 shares of the biopharmaceutical company’s stock worth $246,000 after purchasing an additional 943 shares in the last quarter. Bank of Montreal Can lifted its stake in Horizon Pharma by 16.3% during the second quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock worth $116,000 after purchasing an additional 1,378 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in shares of Horizon Pharma by 1.1% during the second quarter. The Manufacturers Life Insurance Company now owns 125,933 shares of the biopharmaceutical company’s stock worth $1,495,000 after acquiring an additional 1,379 shares during the period. Institutional investors and hedge funds own 86.59% of the company’s stock.

Shares of Horizon Pharma (NASDAQ:HZNP) traded down $0.05 during trading hours on Friday, hitting $14.33. The stock had a trading volume of 2,576,579 shares, compared to its average volume of 3,458,214. The company has a market capitalization of $2,320.00, a P/E ratio of 9.78, a P/E/G ratio of 1.14 and a beta of 1.32. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.52 and a current ratio of 1.64. Horizon Pharma has a 1 year low of $9.45 and a 1 year high of $20.35.

TRADEMARK VIOLATION WARNING: This piece was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/12/01/brokerages-expect-horizon-pharma-plc-hznp-to-announce-0-22-earnings-per-share.html.

About Horizon Pharma

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Get a free copy of the Zacks research report on Horizon Pharma (HZNP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply